Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver.

Liver cytochrome P450s (P450s) play critical roles in drug metabolism, toxicology, and metabolic processes. Despite rapid progress in the understanding of these enzymes, a systematic investigation of the full spectrum of functionality of individual P450s, the interrelationship or networks connecting them, and the genetic control of each gene/enzyme is lacking. To this end, we genotyped, expression-profiled, and measured P450 activities of 466 human liver samples and applied a systems biology approach via the integration of genetics, gene expression, and enzyme activity measurements. We found that most P450s were positively correlated among themselves and were highly correlated with known regulators as well as thousands of other genes enriched for pathways relevant to the metabolism of drugs, fatty acids, amino acids, and steroids. Genome-wide association analyses between genetic polymorphisms and P450 expression or enzyme activities revealed sets of SNPs associated with P450 traits, and suggested the existence of both cis-regulation of P450 expression (especially for CYP2D6) and more complex trans-regulation of P450 activity. Several novel SNPs associated with CYP2D6 expression and enzyme activity were validated in an independent human cohort. By constructing a weighted coexpression network and a Bayesian regulatory network, we defined the human liver transcriptional network structure, uncovered subnetworks representative of the P450 regulatory system, and identified novel candidate regulatory genes, namely, EHHADH, SLC10A1, and AKR1D1. The P450 subnetworks were then validated using gene signatures responsive to ligands of known P450 regulators in mouse and rat. This systematic survey provides a comprehensive view of the functionality, genetic control, and interactions of P450s.

[1]  J. Gustafsson,et al.  LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver Published, JLR Papers in Press, June 1, 2005. DOI 10.1194/jlr.M400453-JLR200 , 2005, Journal of Lipid Research.

[2]  R. Schulte‐Hermann,et al.  Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[3]  J. Lamb,et al.  Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes , 2006, Journal of neurochemistry.

[4]  K. Carroll,et al.  The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. , 2004, Toxicology and applied pharmacology.

[5]  T. A. Richardson,et al.  Regulation of drug-metabolizing enzymes and transporters in inflammation. , 2006, Annual review of pharmacology and toxicology.

[6]  M. Bard,et al.  Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. , 2007, Cell metabolism.

[7]  H. Stefánsson,et al.  Genetics of gene expression and its effect on disease , 2008, Nature.

[8]  J. Castle,et al.  An integrative genomics approach to infer causal associations between gene expression and disease , 2005, Nature Genetics.

[9]  C. Thangavel,et al.  Sexually Dimorphic Regulation of Hepatic Isoforms of Human Cytochrome P450 by Growth Hormone , 2006, Journal of Pharmacology and Experimental Therapeutics.

[10]  B. Ring,et al.  Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[11]  J. Zhu,et al.  An integrative genomics approach to the reconstruction of gene networks in segregating populations , 2004, Cytogenetic and Genome Research.

[12]  J. Pachecka,et al.  Cytochrome P450 polymorphism--molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. , 2008, Acta poloniae pharmaceutica.

[13]  T. Simon,et al.  Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. , 2001, British journal of clinical pharmacology.

[14]  J. Stevens.  New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. , 2006, Drug discovery today.

[15]  Y. Moon,et al.  Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. , 2006, Toxicology in vitro : an international journal published in association with BIBRA.

[16]  R. Barouki,et al.  Repression of cytochrome P450 1A1 gene expression by oxidative stress: mechanisms and biological implications. , 2001, Biochemical pharmacology.

[17]  Jose Cosme,et al.  Crystal structure of human cytochrome P450 2C9 with bound warfarin , 2003, Nature.

[18]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Marohnic,et al.  Cytochromes P450—A Family of Proteins and Scientists–Understanding their Relationships , 2006, Drug metabolism reviews.

[20]  S. Horvath,et al.  Evidence for anti-Burkitt tumour globulins in Burkitt tumour patients and healthy individuals. , 1967, British Journal of Cancer.

[21]  S. Marsh,et al.  Developmental Changes in Human Liver CYP2D6 Expression , 2008, Drug Metabolism and Disposition.

[22]  S. Feng,et al.  Liver‐specific loss of β‐catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice , 2006, Hepatology.

[23]  J. Carlquist,et al.  Cardiovascular Pharmacogenomics: Current Status, Future Prospects , 2003, Journal of cardiovascular pharmacology and therapeutics.

[24]  A. Barabasi,et al.  Hierarchical Organization of Modularity in Metabolic Networks , 2002, Science.

[25]  B. Gibbs,et al.  Regulation of Cytochrome P450 by Posttranslational Modification , 2005, Drug metabolism reviews.

[26]  A. Rettie,et al.  Developmental Expression of Human Hepatic CYP2C9 and CYP2C19 , 2004, Journal of Pharmacology and Experimental Therapeutics.

[27]  L. Gil,et al.  Smoking habit and genetic factors associated with lung cancer in a population highly exposed to arsenic. , 2005, Toxicology letters.

[28]  Celeste Eng,et al.  Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. , 2002, The Journal of clinical investigation.

[29]  R. V. Schaik.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes , 2005, Investigational New Drugs.

[30]  J. Rinn,et al.  Sexual dimorphism in mammalian gene expression. , 2005, Trends in genetics : TIG.

[31]  John D. Storey,et al.  Mapping the Genetic Architecture of Gene Expression in Human Liver , 2008, PLoS biology.

[32]  Alan M. Moses,et al.  Evidence for widespread adaptive evolution of gene expression in budding yeast , 2010, Proceedings of the National Academy of Sciences.

[33]  Bin Zhang,et al.  Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R , 2008, Bioinform..

[34]  J. Castle,et al.  Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome , 2006, Xenobiotica; the fate of foreign compounds in biological systems.

[35]  F. Gonzalez.  Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. , 2008, Drug metabolism and pharmacokinetics.

[36]  S. Horvath,et al.  Variations in DNA elucidate molecular networks that cause disease , 2008, Nature.

[37]  A. Anderson,et al.  Dexamethasone Induction of Murine CYP2B Genes Requires the Glucocorticoid Receptor , 2009, Drug Metabolism and Disposition.

[38]  Wooin Lee,et al.  The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4 , 2003, Nature Medicine.

[39]  F. Oesch,et al.  Association of cytochrome P450 induction with oxidative stress in vivo as evidenced by 3-hydroxylation of salicylate. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[40]  Eun-Young Kim,et al.  Genetic polymorphism of hepatocyte nuclear factor‐4α influences human cytochrome P450 2D6 activity , 2008, Hepatology.

[41]  Yun-Ping Lim,et al.  Interplay of pregnane X receptor with other nuclear receptors on gene regulation. , 2008, Drug metabolism and pharmacokinetics.

[42]  S. Horvath,et al.  Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target , 2006, Proceedings of the National Academy of Sciences.

[43]  M. Ingelman-Sundberg,et al.  Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme , 2008, Human mutation.

[44]  J. Ferrières,et al.  Genetic determinants of response to clopidogrel and cardiovascular events. , 2009, The New England journal of medicine.

[45]  David A. Katz,et al.  Defining drug disposition determinants: a pharmacogenetic–pharmacokinetic strategy , 2008, Nature Reviews Drug Discovery.

[46]  S. Horvath,et al.  A General Framework for Weighted Gene Co-Expression Network Analysis , 2005, Statistical applications in genetics and molecular biology.

[47]  F. Guengerich,et al.  Cytochrome P450 Enzymes , 2010 .

[48]  M. Shimoda,et al.  The impact of acute phase response on the plasma clearance of antipyrine, theophylline, phenytoin and nifedipine in rabbits. , 2000, Journal of veterinary pharmacology and therapeutics.

[49]  M. Sasaki,et al.  The Effect of Aging on the Relationship between the Cytochrome P450 2C19 Genotype and Omeprazole Pharmacokinetics , 2005, Clinical pharmacokinetics.

[50]  B. K. Park.  Cytochrome P450 enzymes in the heart , 2000, The Lancet.

[51]  D. Schrenk,et al.  Tumor promoters as inhibitors of apoptosis in rat hepatocytes. , 2003, Toxicology letters.

[52]  Aiqing He,et al.  Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids , 2006, Proceedings of the National Academy of Sciences.

[53]  E. Antman,et al.  Cytochrome p-450 polymorphisms and response to clopidogrel. , 2009, The New England journal of medicine.

[54]  W. Drake,et al.  Cosegregation of a Novel Homozygous CYP11B1 Mutation with the Phenotype of Non-Classical Congenital Adrenal Hyperplasia in a Consanguineous Family , 2006, Hormone Research in Paediatrics.

[55]  J. Corton,et al.  Regulation of phase I and phase II steroid metabolism enzymes by PPAR alpha activators. , 2004, Toxicology.

[56]  Xia Yang,et al.  Validation of Candidate Causal Genes for Abdominal Obesity Which Affect Shared Metabolic Pathways and Networks , 2009, Nature Genetics.

[57]  Stephen W. Edwards,et al.  Microarray Standard Data Set and Figures of Merit for Comparing Data Processing Methods and Experiment Designs , 2003, Bioinform..

[58]  R. DeBose-Boyd.  A helping hand for cytochrome p450 enzymes. , 2007, Cell metabolism.

[59]  J. Pascussi,et al.  Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites , 2004 .

[60]  W. Xie,et al.  Xenobiotic receptor meets NF-kappaB, a collision in the small bowel. , 2006, Cell metabolism.

[61]  Kai Wang,et al.  Meta-analysis of Inter-species Liver Co-expression Networks Elucidates Traits Associated with Common Human Diseases , 2009, PLoS Comput. Biol..

[62]  D. Lewis,et al.  Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal Structure , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[63]  M. Rao,et al.  Overexpression of peroxisome proliferator-activated receptor-alpha (PPARalpha)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient in both L- and D-forms of enoyl-CoA hydratase/dehydrogenase enzymes of peroxisomal beta-oxidation system. , 2003, The Journal of biological chemistry.

[64]  Jun Zhu,et al.  Increasing the Power to Detect Causal Associations by Combining Genotypic and Expression Data in Segregating Populations , 2007, PLoS Comput. Biol..

[65]  Karl H. Clodfelter,et al.  Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic Acid microarray analysis. , 2004, Molecular endocrinology.

[66]  V. Vasiliou,et al.  Role of CYP1B1 in glaucoma. , 2008, Annual review of pharmacology and toxicology.

[67]  Nick Plant,et al.  The human cytochrome P450 sub-family: transcriptional regulation, inter-individual variation and interaction networks. , 2007, Biochimica et biophysica acta.

[68]  Bin Zhang,et al.  A systems biology approach to drug discovery. , 2008, Advances in genetics.

[69]  Hongyue Dai,et al.  Rosetta error model for gene expression analysis , 2006, Bioinform..

[70]  J. Hakkola,et al.  Developmental expression of cytochrome P450 enzymes in human liver. , 1998, Pharmacology & toxicology.

[71]  Ortiz de Montellano,et al.  Cytochrome P-450: Structure, Mechanism, and Biochemistry , 1986 .

[72]  A. Arnold,et al.  Tissue-specific expression and regulation of sexually dimorphic genes in mice. , 2006, Genome research.

[73]  W. Pryor.  Cytochrome P450: Structure, mechanism, and biochemistry , 1996 .

[74]  Y. Wan,et al.  The role of hepatocyte RXRα in xenobiotic-sensing nuclear receptor-mediated pathways , 2002 .

[75]  Rachel B. Brem,et al.  Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks , 2008, Nature Genetics.

[76]  A. Braeuning.  Regulation of cytochrome P450 expression by Ras- and beta-catenin-dependent signaling. , 2009, Current drug metabolism.

[77]  A. Buchmann,et al.  A beta-catenin-dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. , 2004, Carcinogenesis.

[78]  J. Hardwick.  Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. , 2008, Biochemical pharmacology.

[79]  J. Pascussi,et al.  Transcriptional Regulation of CYP2C9 Gene , 2002, The Journal of Biological Chemistry.

[80]  John Hodgson,et al.  ADMET—turning chemicals into drugs , 2001, Nature Biotechnology.

[81]  A. Daly,et al.  Pharmacogenetics of the cytochromes P450. , 2004, Current topics in medicinal chemistry.

[82]  C. Fontaine,et al.  Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes , 2004, Trends in Endocrinology & Metabolism.

[83]  W. Ambrosius,et al.  The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity , 2003, Clinical pharmacology and therapeutics.

[84]  S. Onishi,et al.  A Missense Mutation (GGC[435Gly]→AGC[Ser]) in Exon 8 of the CYP11B2 Gene Inherited in Japanese Patients with Congenital Hypoaldosteronism , 2003, Hormone Research in Paediatrics.

[85]  Parry Wh.  The Smoking Habit , 1919, The Hospital.

[86]  Lisa M. D'Souza,et al.  Genome sequence of the Brown Norway rat yields insights into mammalian evolution , 2004, Nature.

[87]  A. Gaedigk,et al.  The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.

[88]  J. Grötzinger,et al.  Analyzing the functional and structural consequences of two point mutations (P94L and A368D) in the CYP11B1 gene causing congenital adrenal hyperplasia resulting from 11-hydroxylase deficiency. , 2006, The Journal of clinical endocrinology and metabolism.

[89]  U. Meyer,et al.  Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. , 2004, Pharmacogenetics.

[90]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[91]  G. Kullak-Ublick,et al.  Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. , 2005, Archives of biochemistry and biophysics.

[92]  M. Rao,et al.  Overexpression of Peroxisome Proliferator-activated Receptor-α (PPARα)-regulated Genes in Liver in the Absence of Peroxisome Proliferation in Mice Deficient in both l- and d-Forms of Enoyl-CoA Hydratase/Dehydrogenase Enzymes of Peroxisomal β-Oxidation System* , 2003, Journal of Biological Chemistry.

[93]  Shiyong Chen,et al.  Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. , 2008, Biochemical pharmacology.

[94]  B. Ring,et al.  COMPARATIVE METABOLIC CAPABILITIES OF CYP 3 A 4 , CYP 3 A 5 , AND CYP 3 A 7 , 2002 .

[95]  R. Rosengren,et al.  Sex-specific differences in CYP450 isoforms in humans , 2008, Expert opinion on drug metabolism & toxicology.

[96]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[97]  D. Waxman,et al.  P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. , 1999, Archives of biochemistry and biophysics.

[98]  L. Maltais,et al.  Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. , 2004, Pharmacogenetics.

[99]  G. Anderson.  Gender differences in pharmacological response. , 2008, International review of neurobiology.

[100]  W. Xie,et al.  Xenobiotic receptor meets NF-κB, a collision in the small bowel , 2006 .

[101]  B. Blumberg,et al.  Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. , 2006, The Journal of clinical investigation.

[102]  P. Calderon,et al.  The effect of ageing on cytochrome p450 enzymes: consequences for drug biotransformation in the elderly. , 2007, Current medicinal chemistry.